BioSpace News Archive

Business

Bespoke Gene Therapy Consortium Targets AAVs for Rare Diseases

Launched in 2021, the public-private consortium on Wednesday updated ASGCT attendees on its efforts to bring adeno-associated virus gene therapies to more rare disease patients.

May 9, 2024
·
3 min read
·
Greg Slabodkin
Drug Development

Lisata’s Autologous T Cell Therapy Is Safe but Fails to Slow T1D Disease Progression, Trial Finds

An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve β-cell function.

May 9, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies

The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another for immune-mediated diseases.

May 9, 2024
·
1 min read
·
Tyler Patchen
Policy

FDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy Oversight

At a Thursday ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene therapies, especially for rare diseases.

May 9, 2024
·
3 min read
·
Greg Slabodkin
Drug Development

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop

After a combination with Eisai’s Lenvima failed to improve survival in advanced disease in December, adjuvant Keytruda plus chemotherapy missed the mark in newly diagnosed, high-risk patients.

May 9, 2024
·
1 min read
·
Kate Goodwin
Business

Novo Inks $600M Deal With Metaphore to Develop Next-Gen Obesity Drugs

As competition with Eli Lilly heats up, Novo Nordisk has partnered with Flagship’s Metaphore Biotechnologies to take a biomimicry approach to GLP-1s.

May 9, 2024
·
2 min read
·
Tristan Manalac
Business

Takeda Lowers Profit Outlook Amid Vyvanse Loss of Exclusivity, Eyes $900M Restructuring in 2024

Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven by increasing generic competition for its ADHD treatment Vyvanse.

May 9, 2024
·
2 min read
·
Tristan Manalac
Business

Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced financial results for the three months ended March 31, 2024.

May 9, 2024
·
15 min read
Business

PacBio Announces First Quarter 2024 Financial Results

PacBio announced financial results for the quarter ended March 31, 2024.

May 9, 2024
·
14 min read
Business

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

May 9, 2024
·
16 min read